



## Lypro Biosciences congratulates ABIONYX on initiation of Phase 2a clinical trial with CER-001

January 14, 2021

Alameda, CA – Lypro Biosciences, Inc. (Lypro Bio) congratulates ABIONYX Pharma on the [initiation of its Phase 2a](#) of [CER-001](#) in septic patients with high risk of developing Acute Kidney Injury.

Previous research has demonstrated reconstituted HDLs (rHDL) have a scavenger role in reducing circulating endotoxin as well as anti-inflammatory effects.<sup>1</sup> The addition of a bioactive agent to an rHDL-like particle could add to the effect.

### About Lypro Biosciences

Lypro Biosciences, Inc. is privately-held, nanotechnology company, located in the San Francisco Bay Area. Lypro Bio's proprietary nanotechnology drug delivery platform, NanoDisk, is based on self-assembling, targetable, nanometer-scale bioparticles termed "NanoDisk". It has applications across numerous disease indications. Its proprietary technology was acquired by Abionyx Pharma, [formerly known as Cerenis Therapeutics](#).

### Contact:

Michelle S. Call  
President  
Lypro Biosciences, Inc.  
[info@lyprobio.com](mailto:info@lyprobio.com)  
[www.lyprobio.com](http://www.lyprobio.com)

---

<sup>1</sup> **Pajkrt, D.** *et al.* Anti inflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. *J. Exp. Med.* **184**, 1601–1608 (1996) and **Birjmohun, R. S.** *et al.* High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. *Arterioscler. Thromb. Vasc. Biol.* **27**, 1153–1158 (2007).